Stockreport

SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023) [Yahoo! Finance]

SAB Biotherapeutics, Inc.  (SABS) 
PDF All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is forecast to grow 9.9% p.a. on average during the next 3 year [Read more]